German investment bank Berenberg has lifted its price target on Fresenius to €54, arguing that investors are still valuing the healthcare group as a hospital-heavy conglomerate even though its faster-growing businesses have become the main profit drivers. The bank kept its buy rating, saying the company has not been fully "rewarded" for the shift toward higher-margin operations.
In a note cited by MT Newswires, Berenberg said operating profit (earnings before interest and taxes, or EBIT) from what it calls Fresenius's "growth vectors" – Biopharma (biosimilars), Nutrition, and MedTech – overtook the Pharma unit in the fourth quarter of 2025. That milestone, the bank argues, shows the company's earnings mix is changing in a way the market has yet to fully appreciate.
What is Fresenius and why does this matter?
Fresenius is one of Europe's largest healthcare companies, with roots in dialysis and hospital operations. Its main divisions include Fresenius Medical Care (dialysis), Fresenius Kabi (intravenous drugs and clinical nutrition), and Fresenius Helios (a network of hospitals). For years, the company's fortunes were closely tied to its hospital business, which is capital-intensive and sensitive to government health budgets and staffing costs.
But the company has been repositioning itself. Biosimilars – lower-cost copies of biologic drugs – are a growing market as patents on expensive original biologics expire. Nutrition products, including clinical and parenteral nutrition, offer steady demand and higher margins. MedTech, which includes medical devices and technology, is also seen as a faster-growing area with better profitability than traditional hospital care.
Berenberg's point is that the market still prices Fresenius as if hospitals dominate its earnings, even though the growth businesses now contribute more to operating profit. That disconnect, the bank suggests, is an opportunity for investors.
What could happen on Nov. 4?
The bank's note points to Nov. 4 as a potential catalyst. That is when Fresenius is expected to report its next set of financial results. Berenberg believes the numbers could "surprise" – meaning they might come in better than the market expects – because the growth vectors are now pulling more weight.
For everyday investors, this is a reminder that a company's stock price often reflects what the market already knows. When a company's business mix changes, it can take time for analysts and investors to adjust their models. If Fresenius's upcoming results show that biosimilars, Nutrition, and MedTech are indeed driving profit growth, the stock could re-rate higher.
What it means for investors
Berenberg's price target of €54 implies upside from where the stock has been trading, though the exact current price is not mentioned in the note. The bank's buy rating suggests it sees more room for the shares to rise.
For investors, the key takeaway is that Fresenius is no longer just a hospital operator. The company is increasingly a diversified healthcare group with exposure to faster-growing, higher-margin segments. That shift could make its earnings more resilient and less dependent on the volatile hospital business.
However, it's important to note that Berenberg's view is just one analyst's opinion. Other banks may have different outlooks. Investors should also consider the risks: biosimilars face pricing pressure, Nutrition is a competitive market, and MedTech can be affected by regulatory changes. The hospital business, while shrinking in relative importance, still carries operational and political risks.
Berenberg's optimism on Fresenius is part of a broader theme in European healthcare, where companies are trying to pivot toward higher-growth, higher-margin businesses. Similar dynamics are playing out elsewhere, as seen in ABB's record backlog and data center demand that keep Berenberg bullish on that industrial group. And in the energy sector, Equinor's profit outlook gets a boost from higher European gas prices, showing how analysts are watching for earnings catalysts across industries.
For those following European stocks, the Nov. 4 report will be a key test. If Fresenius delivers the kind of surprise Berenberg expects, it could validate the bank's thesis and attract more attention to the stock. If not, the shares may continue to trade at a discount to the bank's valuation.
As always, no single analyst note should drive an investment decision. But understanding the underlying shift in a company's business can help investors make more informed choices about whether a stock fits their portfolio.
